Jones Trading Starts Phathom Pharmaceuticals (PHAT) at Buy
- Dow, S&P post worst week in months after hawkish Fed spooks investors
- Fed-fueled dollar rises as bears make for exits
- Adobe (ADBE) Edges Higher After Topping Q2 Estimates, Analysts Raise PT on 'Impressive' Performance
- Fed Statement Very Bullish for Tech Stocks, Focus on Cloud and Cyber Stocks - Wedbush
- You Fight Real Physical Inflation With Rate Hikes, Not Talk of Rate Hikes; Buy the Dip in Commodities, Gold Underpriced - Goldman Sachs
Jones Trading analyst Prakhar Agrawal initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Buy rating and a price target of $50.00.
Shares of Phathom Pharmaceuticals closed at $33.99 yesterday.
You May Also Be Interested In
- Phathom Pharmaceuticals (PHAT) Could Generate $1.9B in US Sales - Jefferies
- Argus Starts Xylem (XYL) at Buy
- Jefferies Starts Macrotech Developers Limited (LODHA:IN) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!